Since single-shot immunization with moderate doses of adenovirus-based vaccines has been reported to be effective in eliciting immune protection (Wu et al, 2020) and potentiating the stemness of neoantigen-specific CD8+ T cells (D’Alise et al, 2022; D’Alise et al, 2019), we produced Ad5-vectored neoantigen vaccines in this study to ensure its early application in tumor therapy. The gene discussed is CD8A; the disease is neoplasm.